PepGen (PEPG) Net Equity Issued and Repurchased (2021 - 2026)

PepGen (PEPG) posted Net Equity Issued and Repurchased of $1.5 million for Q1 2026, down 84.74% sequentially from $9.9 million in Q1 2024.

Analysis

PepGen (PEPG) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends

PepGen has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $1.5 million in Q1 2026.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (changed N/A YoY) and the FY2024 annual result came in at $9.9 million, changed N/A from the prior year.
Net Equity Issued and Repurchased retreated to $1.5 million in Q1 2026 per PEPG's latest filing, from $9.9 million in the prior quarter.
Over five years, Net Equity Issued and Repurchased peaked at $9.9 million in Q1 2024 and troughed at $1.5 million in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	141.90 Mn
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	PepGen	217.99 Mn	217.99 Mn	-	-

Historic Data

Download Data